Enrollment Completed in Global Multi-Center Ph 3 Clinical Trial of Trilaciclib in Patients with mTNBC
“TNBC tumors are aggressive and difficult to treat; and while chemotherapy with or without targeted therapy remains first line TNBC standard of care, there is a great need to improve survival beyond that expected from it – particularly without increasing toxicity,” said Raj Malik, M.D., G1’s Chief Medical Officer. “PRESERVE 2 is exciting as it is evaluating trilaciclib in mTNBC to build on the robust survival benefit observed in the Phase 2 program. Completion of enrollment is an important milestone for G1 and the patients we seek to treat, and we look forward to the interim analysis, which is expected to occur in the second half of 2023. This is a registrational trial for which we have been granted Fast Track designation by the U.S. Food and Drug Administration – and if the results are positive, we will work closely with the FDA to expedite our regulatory filing for approval in this indication.”
Share:
More News
“We are pleased to have exceeded our public guidance by advancing our RAS-targeting franchise toward the clinic following our efficient IND execution ahead of schedule. Both ERAS-0015 and ERAS-4001 have the potential to change the treatment paradigm for patients with solid tumors mutated in (K)RAS, the most prevalent oncogenic driver,
“It’s gratifying to see another important benchmark reached in our work to combat pediatric brain cancer,” said Dr. Jeff Sperring, Chief Executive Officer at Seattle Children’s. “Our research is the foundation of progress to bring potential therapies to kids as fast as we can – and we’re excited about the
“CPO301 (also known as SYS6010 in China), a first-in-class epidermal growth factor receptor (‘‘EGFR’’) antibody drug conjugate (ADC), has been granted the third Fast Track designation by the U.S. Food and Drug Administration (‘‘FDA’’) for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC)
“The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “At Incyte, we focus our efforts where we can make the biggest impact for patients. I
